CORDIS
EU research results

CORDIS

English EN
Combatting the CardioRenal Syndrome: towards an integrative Analysis to reduce cardiovascular burden in chronic kidney disease

Combatting the CardioRenal Syndrome: towards an integrative Analysis to reduce cardiovascular burden in chronic kidney disease

Objective

Successfully combatting a complex disease requires multi-disciplinary and methodically well-trained scientists. CaReSyAn strives to accomplish exactly this: we will train scientists to successfully integrate proteomics, clinical, experimental and bioinformatical analyses to enhance the understanding, diagnosis and therapy of the cardiorenal syndrome (CRS). CRS comprises disorders of the heart, vessels and kidneys, including the increased development of cardiovascular disease (CVD) in patients with chronic kidney disease (CKD). With ~45% of all deaths in CKD patients caused by CVD, the socio-economic burden of CRS is extremely high.

CaReSyAn will train scientists in a close cooperation between academia, SME and industry partners. Key objectives are to provide: 1) Excellent scientific training on CRS pathology, integrating clinical/mechanistic knowledge with technological skills (animals and in vitro, molecular and functional studies, proteomics and bioinformatics) to generate innovative insights triggering the understanding, diagnosis and treatment of the CRS; 2) Excellent complementary skills in personal and career development as well as business training required to extend beyond scientific research; and 3) Exposure to both academic and non-academic environments, required to build bridges between researchers and entrepreneurs and support the future translation of research findings in innovative products and services.

CaReSyAn builds on already available patient cohorts, advanced technologies and established cooperations. CaReSyAn is complementary to ongoing European programs focusing solely on CKD or CVD and strives to synergistically improve structural training on European level. CaReSyAn will nurture the development of young, broadly-trained scientists able to successfully bridge clinical with basic research as well as academia and industry. This is a cornerstone in effectively combatting complex diseases as CRS, a major killer of this century.
Leaflet | Map data © OpenStreetMap contributors, Credit: EC-GISCO, © EuroGeographics for the administrative boundaries

Coordinator

UNIVERSITAETSKLINIKUM AACHEN

Address

Pauwelsstrasse 30
52074 Aachen

Germany

Activity type

Higher or Secondary Education Establishments

EU Contribution

€ 747 649,44

Participants (9)

Sort alphabetically

Sort by EU Contribution

Expand all

IDRYMA IATROVIOLOGIKON EREUNON AKADEMIAS ATHINON

Greece

EU Contribution

€ 242 386,92

MOSAIQUES DIAGNOSTICS GMBH

Germany

EU Contribution

€ 249 216,48

MEDIZINISCHE UNIVERSITAET WIEN

Austria

EU Contribution

€ 255 934,08

RD NEPHROLOGIE SAS

France

EU Contribution

€ 262 875,60

INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE

France

EU Contribution

€ 262 875,60

UNIVERSITEIT MAASTRICHT

Netherlands

EU Contribution

€ 255 374,28

KAROLINSKA INSTITUTET

Sweden

EU Contribution

€ 263 659,32

DSM MATERIALS SCIENCE CENTER BV

Netherlands

EU Contribution

€ 255 374,28

DSM R & D SOLUTIONS BV

Netherlands

Partners (5)

Sort alphabetically

Expand all

INSTITUTO INVESTIGACION SANITARIA FUNDACION JIMENEZ DIAZ

KATHOLIEKE UNIVERSITEIT LEUVEN

"EUTox, working group of the ""European Society of Artificial Organs"" (ESAO)"

Bayer Pharma AG

Fresenius Medical Care Deutschland GmbH

Project information

Grant agreement ID: 764474

Status

Ongoing project

  • Start date

    1 January 2018

  • End date

    31 December 2021

Funded under:

H2020-EU.1.3.1.

  • Overall budget:

    € 2 795 346

  • EU contribution

    € 2 795 346

Coordinated by:

UNIVERSITAETSKLINIKUM AACHEN

Germany